ID   APOE_HUMAN              Reviewed;         317 AA.
AC   P02649; B2RC15; C0JYY5; Q9P2S4;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   10-MAY-2017, entry version 220.
DE   RecName: Full=Apolipoprotein E;
DE            Short=Apo-E;
DE   Flags: Precursor;
GN   Name=APOE;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (VARIANT E3).
RX   PubMed=6325438;
RA   Zannis V.I., McPherson J., Goldberger G., Karathanasis S.K.,
RA   Breslow J.L.;
RT   "Synthesis, intracellular processing, and signal peptide of human
RT   apolipoprotein E.";
RL   J. Biol. Chem. 259:5495-5499(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (VARIANT E3).
RX   PubMed=6327682;
RA   McLean J.W., Elshourbagy N.A., Chang D.J., Mahley R.W., Taylor J.M.;
RT   "Human apolipoprotein E mRNA. cDNA cloning and nucleotide sequencing
RT   of a new variant.";
RL   J. Biol. Chem. 259:6498-6504(1984).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (VARIANT E4).
RX   PubMed=2987927; DOI=10.1073/pnas.82.10.3445;
RA   Paik Y.-K., Chang D.J., Reardon C.A., Davies G.E., Mahley R.W.,
RA   Taylor J.M.;
RT   "Nucleotide sequence and structure of the human apolipoprotein E
RT   gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:3445-3449(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (VARIANT E2).
RX   PubMed=3243553; DOI=10.1016/0888-7543(88)90130-9;
RA   Emi M., Wu L.L., Robertson M.A., Myers R.L., Hegele R.A.,
RA   Williams R.R., White R., Lalouel J.-M.;
RT   "Genotyping and sequence analysis of apolipoprotein E isoforms.";
RL   Genomics 3:373-379(1988).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10520737; DOI=10.3109/10425179809086433;
RA   Freitas E.M., Zhang W.J., Lalonde J.P., Tay G.K., Gaudieri S.,
RA   Ashworth L.K., Van Bockxmeer F.M., Dawkins R.L.;
RT   "Sequencing of 42kb of the APO E-C2 gene cluster reveals a new gene:
RT   PEREC1.";
RL   DNA Seq. 9:89-100(1998).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-46; ARG-130;
RP   CYS-163 AND CYS-176.
RX   PubMed=11042151; DOI=10.1101/gr.146900;
RA   Nickerson D.A., Taylor S.L., Fullerton S.M., Weiss K.M., Clark A.G.,
RA   Stengard J.H., Salomaa V., Boerwinkle E., Sing C.F.;
RT   "Sequence diversity and large-scale typing of SNPs in the human
RT   apolipoprotein E gene.";
RL   Genome Res. 10:1532-1545(2000).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 16-78, AND VARIANT HIS-64.
RC   TISSUE=Blood;
RA   Imura T., Kimura H., Kawasaki M.;
RT   "A new apolipoprotein E variant (Gln46-->His).";
RL   Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 99-317 (VARIANT E3).
RX   PubMed=6897404;
RA   Breslow J.L., McPherson J., Nussbaum A.L., Williams H.W.,
RA   Lofquist-Kahl F., Karathanasis S.K., Zannis V.I.;
RT   "Identification and DNA sequence of a human apolipoprotein E cDNA
RT   clone.";
RL   J. Biol. Chem. 257:14639-14641(1982).
RN   [12]
RP   ERRATUM.
RA   Breslow J.L., McPherson J., Nussbaum A.L., Williams H.W.,
RA   Lofquist-Kahl F., Karathanasis S.K., Zannis V.I.;
RL   J. Biol. Chem. 258:11422-11422(1983).
RN   [13]
RP   PROTEIN SEQUENCE OF 19-317 (VARIANT E2).
RX   PubMed=7068630;
RA   Rall S.C. Jr., Weisgraber K.H., Mahley R.W.;
RT   "Human apolipoprotein E. The complete amino acid sequence.";
RL   J. Biol. Chem. 257:4171-4178(1982).
RN   [14]
RP   REVIEW.
RX   PubMed=3283935; DOI=10.1126/science.3283935;
RA   Mahley R.W.;
RT   "Apolipoprotein E: cholesterol transport protein with expanding role
RT   in cell biology.";
RL   Science 240:622-630(1988).
RN   [15]
RP   HEPARIN-BINDING SITES.
RX   PubMed=3947350; DOI=10.1016/S0006-291X(86)80489-2;
RA   Cardin A.D., Hirose N., Blankenship D.T., Jackson R.L.,
RA   Harmony J.A.K., Sparrow D.A., Sparrow J.T.;
RT   "Binding of a high reactive heparin to human apolipoprotein E:
RT   identification of two heparin-binding domains.";
RL   Biochem. Biophys. Res. Commun. 134:783-789(1986).
RN   [16]
RP   ASSOCIATION OF APOE*4 WITH ALZHEIMER DISEASE.
RX   PubMed=8346443; DOI=10.1126/science.8346443;
RA   Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E.,
RA   Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A.;
RT   "Gene dose of apolipoprotein E type 4 allele and the risk of
RT   Alzheimer's disease in late onset families.";
RL   Science 261:921-923(1993).
RN   [17]
RP   GLYCATION AT LYS-93, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=10452964; DOI=10.1016/S0925-4439(99)00047-2;
RA   Shuvaev V.V., Fujii J., Kawasaki Y., Itoh H., Hamaoka R., Barbier A.,
RA   Ziegler O., Siest G., Taniguchi N.;
RT   "Glycation of apolipoprotein E impairs its binding to heparin:
RT   identification of the major glycation site.";
RL   Biochim. Biophys. Acta 1454:296-308(1999).
RN   [18]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT THR-212; THR-307 AND SER-308,
RP   AND STRUCTURE OF CARBOHYDRATES.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=19838169; DOI=10.1038/nmeth.1392;
RA   Nilsson J., Rueetschi U., Halim A., Hesse C., Carlsohn E.,
RA   Brinkmalm G., Larson G.;
RT   "Enrichment of glycopeptides for glycan structure and attachment site
RT   identification.";
RL   Nat. Methods 6:809-811(2009).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S.,
RA   Fischer-Posovszky P., Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion
RT   profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [21]
RP   GLYCOSYLATION AT THR-26; THR-36 AND SER-314, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=23234360; DOI=10.1021/pr300963h;
RA   Halim A., Ruetschi U., Larson G., Nilsson J.;
RT   "LC-MS/MS characterization of O-glycosylation sites and glycan
RT   structures of human cerebrospinal fluid glycoproteins.";
RL   J. Proteome Res. 12:573-584(2013).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-147, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [23]
RP   PHOSPHORYLATION AT SER-147.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 41-184, AND LDL RECEPTOR
RP   BINDING REGION.
RX   PubMed=2063194; DOI=10.1126/science.2063194;
RA   Wilson C., Wardell M.R., Weisgraber K.H., Mahley R.W., Agard D.A.;
RT   "Three-dimensional structure of the LDL receptor-binding domain of
RT   human apolipoprotein E.";
RL   Science 252:1817-1822(1991).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 41-181.
RX   PubMed=8756331; DOI=10.1038/nsb0896-718;
RA   Dong L.-M., Parkin S., Trakhanov S.D., Rupp B., Simmons T.,
RA   Arnold K.S., Newhouse Y.M., Innerarity T.L., Weisgraber K.H.;
RT   "Novel mechanism for defective receptor binding of apolipoprotein E2
RT   in type III hyperlipoproteinemia.";
RL   Nat. Struct. Biol. 3:718-722(1996).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 22-165.
RX   PubMed=10850798; DOI=10.1110/ps.9.5.886;
RA   Segelke B.W., Forstner M., Knapp M., Trakhanov S.D., Parkin S.,
RA   Newhouse Y.M., Bellamy H.D., Weisgraber K.H., Rupp B.;
RT   "Conformational flexibility in the apolipoprotein E amino-terminal
RT   domain structure determined from three new crystal forms: implications
RT   for lipid binding.";
RL   Protein Sci. 9:886-897(2000).
RN   [27]
RP   REVIEW ON VARIANTS.
RX   PubMed=7833947; DOI=10.1002/humu.1380040303;
RA   de Knijff P., van den Maagdenberg A.M.J.M., Frants R.R., Havekes L.M.;
RT   "Genetic heterogeneity of apolipoprotein E and its influence on plasma
RT   lipid and lipoprotein levels.";
RL   Hum. Mutat. 4:178-194(1994).
RN   [28]
RP   VARIANT E5 LYS-21.
RX   PubMed=2760009; DOI=10.1093/oxfordjournals.jbchem.a122692;
RA   Maeda H., Nakamura H., Kobori S., Okada M., Niki H., Ogura T.,
RA   Hiraga S.;
RT   "Molecular cloning of a human apolipoprotein E variant: E5 (Glu-
RT   3-->Lys).";
RL   J. Biochem. 105:491-493(1989).
RN   [29]
RP   VARIANT HLPP3 E3 LEIDEN GLU-VAL-GLN-ALA-MET-LEU-GLY-145 INS.
RX   PubMed=2556398;
RA   Wardell M.R., Weisgraber K.H., Havekes L.M., Rall S.C. Jr.;
RT   "Apolipoprotein E3-Leiden contains a seven-amino acid insertion that
RT   is a tandem repeat of residues 121-127.";
RL   J. Biol. Chem. 264:21205-21210(1989).
RN   [30]
RP   VARIANTS HLPP3 E4 PHILADELPHIA LYS-31 AND CYS-163.
RX   PubMed=1674745;
RA   Lohse P., Mann W.A., Stein E.A., Brewer H.B. Jr.;
RT   "Apolipoprotein E-4 Philadelphia (Glu-13-->Lys,Arg-145-->Cys).
RT   Homozygosity for two rare point mutations in the apolipoprotein E gene
RT   combined with severe type III hyperlipoproteinemia.";
RL   J. Biol. Chem. 266:10479-10484(1991).
RN   [31]
RP   VARIANTS GLU-254; GLY-269; GLU-270; HIS-292 AND ARG-314.
RX   PubMed=8488843;
RA   van den Maagdenberg A.M.J.M., Weng W., de Bruijn I.H., de Knijff P.,
RA   Funke H., Smelt A.H.M., Leuven J.A.G., van 't Hooft F.M., Assmann G.,
RA   Hofker M.H., Havekes L.M., Frants R.R.;
RT   "Characterization of five new mutants in the carboxyl-terminal domain
RT   of human apolipoprotein E: no cosegregation with severe
RT   hyperlipidemia.";
RL   Am. J. Hum. Genet. 52:937-946(1993).
RN   [32]
RP   VARIANTS HLPP3 ARG-130; ASP-145; SER-154; CYS-160 AND CYS-176.
RX   PubMed=8287539;
RA   Richard P., Thomas G., de Zulueta M.P., de Gennes J.-L., Thomas M.,
RA   Cassaigne A., Bereziat G., Iron A.;
RT   "Common and rare genotypes of human apolipoprotein E determined by
RT   specific restriction profiles of polymerase chain reaction-amplified
RT   DNA.";
RL   Clin. Chem. 40:24-29(1994).
RN   [33]
RP   VARIANT LPG PRO-163.
RX   PubMed=9176854;
RA   Oikawa S., Matsunaga A., Saito T., Sato H., Seki T., Hoshi K.,
RA   Hayasaka K., Kotake H., Midorikawa H., Sekikawa A., Hara S., Abe K.,
RA   Toyota T., Jingami H., Nakamura H., Sasaki J.;
RT   "Apolipoprotein E Sendai (arginine 145-->proline): a new variant
RT   associated with lipoprotein glomerulopathy.";
RL   J. Am. Soc. Nephrol. 8:820-823(1997).
RN   [34]
RP   VARIANTS E4/3 ARG-130 AND GLY-269.
RX   PubMed=9360638; DOI=10.1016/S1383-5726(97)00009-5;
RA   Kang A.K., Jenkins D.J.A., Wolever T.M.S., Huff M.W., Maguire G.F.,
RA   Connelly P.W., Hegele R.A.;
RT   "Apolipoprotein E R112; R251G: a carboxy-terminal variant found in
RT   patients with hyperlipidemia and coronary heart disease.";
RL   Mutat. Res. 382:57-65(1997).
RN   [35]
RP   VARIANT LPG CYS-43.
RX   PubMed=10432380; DOI=10.1046/j.1523-1755.1999.00572.x;
RA   Matsunaga A., Sasaki J., Komatsu T., Kanatsu K., Tsuji E.,
RA   Moriyama K., Koga T., Arakawa K., Oikawa S., Saito T., Kita T.,
RA   Doi T.;
RT   "A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein
RT   glomerulopathy.";
RL   Kidney Int. 56:421-427(1999).
RN   [36]
RP   VARIANT SBHD LEU-167 DEL.
RX   PubMed=11095479; DOI=10.1210/jcem.85.11.6981;
RA   Nguyen T.T., Kruckeberg K.E., O'Brien J.F., Ji Z.-S., Karnes P.S.,
RA   Crotty T.B., Hay I.D., Mahley R.W., O'Brien T.;
RT   "Familial splenomegaly: macrophage hypercatabolism of lipoproteins
RT   associated with apolipoprotein E mutation [apolipoprotein E (delta149
RT   Leu)].";
RL   J. Clin. Endocrinol. Metab. 85:4354-4358(2000).
RN   [37]
RP   VARIANT E3 BASEL VAL-124.
RX   PubMed=12864777; DOI=10.1046/j.1365-2362.2003.01180.x;
RA   Miserez A.R., Scharnagl H., Muller P.Y., Mirsaidi R., Stahelin H.B.,
RA   Monsch A., Marz W., Hoffmann M.M.;
RT   "Apolipoprotein E3Basel: new insights into a highly conserved protein
RT   region.";
RL   Eur. J. Clin. Invest. 33:677-685(2003).
RN   [38]
RP   VARIANTS ARG-130 AND CYS-176.
RX   PubMed=12966036; DOI=10.1093/hmg/ddg314;
RA   Morabia A., Cayanis E., Costanza M.C., Ross B.M., Flaherty M.S.,
RA   Alvin G.B., Das K., Gilliam T.C.;
RT   "Association of extreme blood lipid profile phenotypic variation with
RT   11 reverse cholesterol transport genes and 10 non-genetic
RT   cardiovascular disease risk factors.";
RL   Hum. Mol. Genet. 12:2733-2743(2003).
RN   [39]
RP   VARIANT SBHD LEU-167 DEL.
RX   PubMed=16094309; DOI=10.1038/sj.ejhg.5201480;
RA   Faivre L., Saugier-Veber P., Pais de Barros J.-P., Verges B.,
RA   Couret B., Lorcerie B., Thauvin C., Charbonnier F., Huet F.,
RA   Gambert P., Frebourg T., Duvillard L.;
RT   "Variable expressivity of the clinical and biochemical phenotype
RT   associated with the apolipoprotein E p.Leu149del mutation.";
RL   Eur. J. Hum. Genet. 13:1186-1191(2005).
RN   [40]
RP   VARIANT LPG CYS-43.
RX   PubMed=18077821; DOI=10.1056/NEJMc072088;
RA   Rovin B.H., Roncone D., McKinley A., Nadasdy T., Korbet S.M.,
RA   Schwartz M.M.;
RT   "APOE Kyoto mutation in European Americans with lipoprotein
RT   glomerulopathy.";
RL   N. Engl. J. Med. 357:2522-2524(2007).
RN   [41]
RP   VARIANT HIS-64, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22028381; DOI=10.1093/jmcb/mjr024;
RA   Su Z.D., Sun L., Yu D.X., Li R.X., Li H.X., Yu Z.J., Sheng Q.H.,
RA   Lin X., Zeng R., Wu J.R.;
RT   "Quantitative detection of single amino acid polymorphisms by targeted
RT   proteomics.";
RL   J. Mol. Cell Biol. 3:309-315(2011).
RN   [42]
RP   VARIANT HLPP3 SER-154, AND VARIANT LEU-167 DEL.
RX   PubMed=22481068; DOI=10.1016/j.atherosclerosis.2012.03.011;
RA   Solanas-Barca M., de Castro-Oros I., Mateo-Gallego R., Cofan M.,
RA   Plana N., Puzo J., Burillo E., Martin-Fuentes P., Ros E., Masana L.,
RA   Pocovi M., Civeira F., Cenarro A.;
RT   "Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia
RT   and a clinical diagnosis of familial combined hyperlipidemia.";
RL   Atherosclerosis 222:449-455(2012).
RN   [43]
RP   POSSIBLE INVOLVEMENT IN FH, AND VARIANT FH LEU-167 DEL.
RX   PubMed=24267230; DOI=10.1016/j.atherosclerosis.2013.09.007;
RA   Awan Z., Choi H.Y., Stitziel N., Ruel I., Bamimore M.A., Husa R.,
RA   Gagnon M.H., Wang R.H., Peloso G.M., Hegele R.A., Seidah N.G.,
RA   Kathiresan S., Genest J.;
RT   "APOE p.Leu167del mutation in familial hypercholesterolemia.";
RL   Atherosclerosis 231:218-222(2013).
RN   [44]
RP   POSSIBLE INVOLVEMENT IN FH, AND VARIANT FH LEU-167 DEL.
RX   PubMed=22949395; DOI=10.1002/humu.22215;
RA   Marduel M., Ouguerram K., Serre V., Bonnefont-Rousselot D.,
RA   Marques-Pinheiro A., Erik Berge K., Devillers M., Luc G., Lecerf J.M.,
RA   Tosolini L., Erlich D., Peloso G.M., Stitziel N., Nitchke P.,
RA   Jais J.P., Abifadel M., Kathiresan S., Leren T.P., Rabes J.P.,
RA   Boileau C., Varret M.;
RT   "Description of a large family with autosomal dominant
RT   hypercholesterolemia associated with the APOE p.Leu167del mutation.";
RL   Hum. Mutat. 34:83-87(2013).
RN   [45]
RP   POSSIBLE INVOLVEMENT IN FH, AND VARIANTS FH PRO-46; ASP-145; CYS-163
RP   AND LEU-167 DEL.
RX   PubMed=26802169; DOI=10.1194/jlr.P055699;
RA   Wintjens R., Bozon D., Belabbas K., Mbou F., Girardet J.P.,
RA   Tounian P., Jolly M., Boccara F., Cohen A., Karsenty A., Dubern B.,
RA   Carel J.C., Azar-Kolakez A., Feillet F., Labarthe F., Gorsky A.M.,
RA   Horovitz A., Tamarindi C., Kieffer P., Lienhardt A., Lascols O.,
RA   Di Filippo M., Dufernez F.;
RT   "Global molecular analysis and APOE mutations in a cohort of autosomal
RT   dominant hypercholesterolemia patients in France.";
RL   J. Lipid Res. 57:482-491(2016).
CC   -!- FUNCTION: Mediates the binding, internalization, and catabolism of
CC       lipoprotein particles. It can serve as a ligand for the LDL (apo
CC       B/E) receptor and for the specific apo-E receptor (chylomicron
CC       remnant) of hepatic tissues. {ECO:0000303|PubMed:3283935}.
CC   -!- INTERACTION:
CC       P27958:- (xeno); NbExp=4; IntAct=EBI-1222467, EBI-6904269;
CC       Q16543:CDC37; NbExp=3; IntAct=EBI-1222467, EBI-295634;
CC       Q9BQ95:ECSIT; NbExp=4; IntAct=EBI-1222467, EBI-712452;
CC       P00738:HP; NbExp=7; IntAct=EBI-1222467, EBI-1220767;
CC       P01130:LDLR; NbExp=2; IntAct=EBI-1222467, EBI-988319;
CC       Q14114:LRP8; NbExp=2; IntAct=EBI-1222467, EBI-2681187;
CC       P10636:MAPT; NbExp=3; IntAct=EBI-9209835, EBI-366182;
CC       Q53EL6:PDCD4; NbExp=3; IntAct=EBI-1222467, EBI-935824;
CC       P50502:ST13; NbExp=3; IntAct=EBI-1222467, EBI-357285;
CC       O75069:TMCC2; NbExp=5; IntAct=EBI-1222467, EBI-726731;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000303|PubMed:3283935}.
CC   -!- TISSUE SPECIFICITY: Occurs in all lipoprotein fractions in plasma.
CC       It constitutes 10-20% of very low density lipoproteins (VLDL) and
CC       1-2% of high density lipoproteins (HDL). APOE is produced in most
CC       organs. Significant quantities are produced in liver, brain,
CC       spleen, lung, adrenal, ovary, kidney and muscle.
CC   -!- PTM: Synthesized with the sialic acid attached by O-glycosidic
CC       linkage and is subsequently desialylated in plasma. O-glycosylated
CC       with core 1 or possibly core 8 glycans. Thr-307 and Ser-314 are
CC       minor glycosylation sites compared to Ser-308.
CC       {ECO:0000269|PubMed:19838169, ECO:0000269|PubMed:23234360}.
CC   -!- PTM: Glycated in plasma VLDL of normal subjects, and of
CC       hyperglycemic diabetic patients at a higher level (2-3 fold).
CC   -!- PTM: Phosphorylated by FAM20C in the extracellular medium.
CC       {ECO:0000269|PubMed:26091039}.
CC   -!- POLYMORPHISM: Three common APOE alleles have been identified:
CC       APOE*2, APOE*3, and APOE*4. The corresponding three major
CC       isoforms, E2, E3, and E4, are recognized according to their
CC       relative position after isoelectric focusing. Different mutations
CC       causing the same migration pattern after isoelectric focusing
CC       define different isoform subtypes. The most common isoform is E3
CC       and is present in 40-90% of the population. Common APOE variants
CC       influence lipoprotein metabolism in healthy individuals.
CC       {ECO:0000305}.
CC   -!- DISEASE: Hyperlipoproteinemia 3 (HLPP3) [MIM:617347]: A disorder
CC       characterized by the accumulation of intermediate-density
CC       lipoprotein particles (IDL or broad-beta-lipoprotein) rich in
CC       cholesterol. Clinical features include xanthomas, yellowish lipid
CC       deposits in the palmar crease, or less specific on tendons and on
CC       elbows. The disorder rarely manifests before the third decade in
CC       men. In women, it is usually expressed only after the menopause.
CC       {ECO:0000269|PubMed:1674745, ECO:0000269|PubMed:22481068,
CC       ECO:0000269|PubMed:2556398, ECO:0000269|PubMed:8287539}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry. The vast majority of the patients are homozygous for
CC       APOE*2 alleles. More severe cases of HLPP3 have also been observed
CC       in individuals heterozygous for rare APOE variants. The influence
CC       of APOE on lipid levels is often suggested to have major
CC       implications for the risk of coronary artery disease (CAD).
CC       Individuals carrying the common APOE*4 variant are at higher risk
CC       of CAD.
CC   -!- DISEASE: Alzheimer disease 2 (AD2) [MIM:104310]: A late-onset
CC       neurodegenerative disorder characterized by progressive dementia,
CC       loss of cognitive abilities, and deposition of fibrillar amyloid
CC       proteins as intraneuronal neurofibrillary tangles, extracellular
CC       amyloid plaques and vascular amyloid deposits. The major
CC       constituent of these plaques is the neurotoxic amyloid-beta-APP
CC       40-42 peptide (s), derived proteolytically from the transmembrane
CC       precursor protein APP by sequential secretase processing. The
CC       cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved
CC       products such as C31 derived from APP, are also implicated in
CC       neuronal death. Note=Disease susceptibility is associated with
CC       variations affecting the gene represented in this entry. The
CC       APOE*4 allele is genetically associated with the common late onset
CC       familial and sporadic forms of Alzheimer disease. Risk for AD
CC       increased from 20% to 90% and mean age at onset decreased from 84
CC       to 68 years with increasing number of APOE*4 alleles in 42
CC       families with late onset AD. Thus APOE*4 gene dose is a major risk
CC       factor for late onset AD and, in these families, homozygosity for
CC       APOE*4 was virtually sufficient to cause AD by age 80. The
CC       mechanism by which APOE*4 participates in pathogenesis is not
CC       known.
CC   -!- DISEASE: Sea-blue histiocyte disease (SBHD) [MIM:269600]:
CC       Characterized by splenomegaly, mild thrombocytopenia and, in the
CC       bone marrow, numerous histiocytes containing cytoplasmic granules
CC       which stain bright blue with the usual hematologic stains. The
CC       syndrome is the consequence of an inherited metabolic defect
CC       analogous to Gaucher disease and other sphingolipidoses.
CC       {ECO:0000269|PubMed:11095479, ECO:0000269|PubMed:16094309}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Lipoprotein glomerulopathy (LPG) [MIM:611771]: Uncommon
CC       kidney disease characterized by proteinuria, progressive kidney
CC       failure, and distinctive lipoprotein thrombi in glomerular
CC       capillaries. {ECO:0000269|PubMed:10432380,
CC       ECO:0000269|PubMed:18077821, ECO:0000269|PubMed:9176854}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Familial hypercholesterolemia (FH) [MIM:143890]: Common
CC       autosomal semi-dominant disease that affects about 1 in 500
CC       individuals. The receptor defect impairs the catabolism of LDL,
CC       and the resultant elevation in plasma LDL-cholesterol promotes
CC       deposition of cholesterol in the skin (xanthelasma), tendons
CC       (xanthomas), and coronary arteries (atherosclerosis).
CC       {ECO:0000269|PubMed:22949395, ECO:0000269|PubMed:24267230,
CC       ECO:0000269|PubMed:26802169}. Note=The disease may be caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the apolipoprotein A1/A4/E family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=APOE";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Apolipoprotein E entry;
CC       URL="https://en.wikipedia.org/wiki/Apolipoprotein_E";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=Tangled - Issue 83 of
CC       June 2007;
CC       URL="http://web.expasy.org/spotlight/back_issues/083";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M12529; AAB59518.1; -; mRNA.
DR   EMBL; K00396; AAB59546.1; -; mRNA.
DR   EMBL; M10065; AAB59397.1; -; Genomic_DNA.
DR   EMBL; AF050154; AAD02505.1; -; Genomic_DNA.
DR   EMBL; AF261279; AAG27089.1; -; Genomic_DNA.
DR   EMBL; AK314898; BAG37412.1; -; mRNA.
DR   EMBL; FJ525876; ACN81314.1; -; Genomic_DNA.
DR   EMBL; BC003557; AAH03557.1; -; mRNA.
DR   EMBL; AB035149; BAA96080.1; -; Genomic_DNA.
DR   CCDS; CCDS12647.1; -.
DR   PIR; A92478; LPHUE.
DR   RefSeq; NP_000032.1; NM_000041.3.
DR   RefSeq; NP_001289617.1; NM_001302688.1.
DR   RefSeq; NP_001289618.1; NM_001302689.1.
DR   RefSeq; NP_001289619.1; NM_001302690.1.
DR   RefSeq; NP_001289620.1; NM_001302691.1.
DR   UniGene; Hs.654439; -.
DR   PDB; 1B68; X-ray; 2.00 A; A=19-209.
DR   PDB; 1BZ4; X-ray; 1.85 A; A=40-183.
DR   PDB; 1EA8; X-ray; 1.95 A; A=19-209.
DR   PDB; 1GS9; X-ray; 1.70 A; A=19-183.
DR   PDB; 1H7I; X-ray; 1.90 A; A=19-209.
DR   PDB; 1LE2; X-ray; 3.00 A; A=41-184.
DR   PDB; 1LE4; X-ray; 2.50 A; A=41-184.
DR   PDB; 1LPE; X-ray; 2.25 A; A=41-184.
DR   PDB; 1NFN; X-ray; 1.80 A; A=19-209.
DR   PDB; 1NFO; X-ray; 2.00 A; A=19-209.
DR   PDB; 1OEF; NMR; -; A=281-304.
DR   PDB; 1OEG; NMR; -; A=285-307.
DR   PDB; 1OR2; X-ray; 2.50 A; A=19-183.
DR   PDB; 1OR3; X-ray; 1.73 A; A=19-183.
DR   PDB; 2KC3; NMR; -; A=19-201.
DR   PDB; 2KNY; NMR; -; A=147-167.
DR   PDB; 2L7B; NMR; -; A=19-317.
DR   PDBsum; 1B68; -.
DR   PDBsum; 1BZ4; -.
DR   PDBsum; 1EA8; -.
DR   PDBsum; 1GS9; -.
DR   PDBsum; 1H7I; -.
DR   PDBsum; 1LE2; -.
DR   PDBsum; 1LE4; -.
DR   PDBsum; 1LPE; -.
DR   PDBsum; 1NFN; -.
DR   PDBsum; 1NFO; -.
DR   PDBsum; 1OEF; -.
DR   PDBsum; 1OEG; -.
DR   PDBsum; 1OR2; -.
DR   PDBsum; 1OR3; -.
DR   PDBsum; 2KC3; -.
DR   PDBsum; 2KNY; -.
DR   PDBsum; 2L7B; -.
DR   ProteinModelPortal; P02649; -.
DR   SMR; P02649; -.
DR   BioGrid; 106845; 58.
DR   DIP; DIP-1120N; -.
DR   IntAct; P02649; 31.
DR   MINT; MINT-4999641; -.
DR   STRING; 9606.ENSP00000252486; -.
DR   DrugBank; DB00062; Human Serum Albumin.
DR   DrugBank; DB00064; Serum albumin iodonated.
DR   iPTMnet; P02649; -.
DR   PhosphoSitePlus; P02649; -.
DR   SwissPalm; P02649; -.
DR   UniCarbKB; P02649; -.
DR   BioMuta; APOE; -.
DR   DMDM; 114039; -.
DR   DOSAC-COBS-2DPAGE; P02649; -.
DR   SWISS-2DPAGE; P02649; -.
DR   EPD; P02649; -.
DR   MaxQB; P02649; -.
DR   PaxDb; P02649; -.
DR   PeptideAtlas; P02649; -.
DR   PRIDE; P02649; -.
DR   DNASU; 348; -.
DR   Ensembl; ENST00000252486; ENSP00000252486; ENSG00000130203.
DR   GeneID; 348; -.
DR   KEGG; hsa:348; -.
DR   UCSC; uc002pab.4; human.
DR   CTD; 348; -.
DR   DisGeNET; 348; -.
DR   GeneCards; APOE; -.
DR   HGNC; HGNC:613; APOE.
DR   HPA; CAB008363; -.
DR   HPA; CAB069921; -.
DR   HPA; HPA065539; -.
DR   HPA; HPA068768; -.
DR   MalaCards; APOE; -.
DR   MIM; 104310; phenotype.
DR   MIM; 107741; gene.
DR   MIM; 143890; phenotype.
DR   MIM; 269600; phenotype.
DR   MIM; 611771; phenotype.
DR   MIM; 617347; phenotype.
DR   neXtProt; NX_P02649; -.
DR   OpenTargets; ENSG00000130203; -.
DR   Orphanet; 238616; Alzheimer disease.
DR   Orphanet; 1648; Dementia with Lewy body.
DR   Orphanet; 406; Heterozygous familial hypercholesterolemia.
DR   Orphanet; 412; Hyperlipoproteinemia type 3.
DR   Orphanet; 329481; Lipoprotein glomerulopathy.
DR   Orphanet; 158029; Sea-blue histiocytosis.
DR   PharmGKB; PA55; -.
DR   eggNOG; ENOG410IVK0; Eukaryota.
DR   eggNOG; ENOG4111MYC; LUCA.
DR   GeneTree; ENSGT00730000111315; -.
DR   HOGENOM; HOG000034006; -.
DR   HOVERGEN; HBG010582; -.
DR   InParanoid; P02649; -.
DR   KO; K04524; -.
DR   OMA; MGSRTRD; -.
DR   OrthoDB; EOG091G0IA5; -.
DR   PhylomeDB; P02649; -.
DR   TreeFam; TF334458; -.
DR   Reactome; R-HSA-174800; Chylomicron-mediated lipid transport.
DR   Reactome; R-HSA-194223; HDL-mediated lipid transport.
DR   Reactome; R-HSA-3000480; Scavenging by Class A Receptors.
DR   Reactome; R-HSA-8864260; Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   SIGNOR; P02649; -.
DR   ChiTaRS; APOE; human.
DR   EvolutionaryTrace; P02649; -.
DR   GeneWiki; Apolipoprotein_E; -.
DR   GenomeRNAi; 348; -.
DR   PMAP-CutDB; P02649; -.
DR   PRO; PR:P02649; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000130203; -.
DR   CleanEx; HS_APOE; -.
DR   ExpressionAtlas; P02649; baseline and differential.
DR   Genevisible; P02649; HS.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0042627; C:chylomicron; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; TAS:UniProtKB.
DR   GO; GO:0030425; C:dendrite; NAS:BHF-UCL.
DR   GO; GO:0005769; C:early endosome; TAS:Reactome.
DR   GO; GO:0071682; C:endocytic vesicle lumen; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:AgBase.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IDA:ARUK-UCL.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:1903561; C:extracellular vesicle; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:AgBase.
DR   GO; GO:0034364; C:high-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0034363; C:intermediate-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0034362; C:low-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; NAS:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0034361; C:very-low-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0016209; F:antioxidant activity; IDA:BHF-UCL.
DR   GO; GO:0001540; F:beta-amyloid binding; IDA:UniProtKB.
DR   GO; GO:0015485; F:cholesterol binding; IBA:GO_Central.
DR   GO; GO:0017127; F:cholesterol transporter activity; IBA:GO_Central.
DR   GO; GO:0008201; F:heparin binding; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IDA:BHF-UCL.
DR   GO; GO:0008289; F:lipid binding; IDA:UniProtKB.
DR   GO; GO:0005319; F:lipid transporter activity; IDA:BHF-UCL.
DR   GO; GO:0071813; F:lipoprotein particle binding; IEA:Ensembl.
DR   GO; GO:0050750; F:low-density lipoprotein particle receptor binding; IDA:BHF-UCL.
DR   GO; GO:0046911; F:metal chelating activity; IDA:BHF-UCL.
DR   GO; GO:0060228; F:phosphatidylcholine-sterol O-acyltransferase activator activity; IDA:BHF-UCL.
DR   GO; GO:0005543; F:phospholipid binding; IDA:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:ARUK-UCL.
DR   GO; GO:0048156; F:tau protein binding; IPI:BHF-UCL.
DR   GO; GO:0070326; F:very-low-density lipoprotein particle receptor binding; IDA:BHF-UCL.
DR   GO; GO:0097113; P:AMPA glutamate receptor clustering; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0048844; P:artery morphogenesis; IEA:Ensembl.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0019934; P:cGMP-mediated signaling; IDA:BHF-UCL.
DR   GO; GO:0006707; P:cholesterol catabolic process; IBA:GO_Central.
DR   GO; GO:0033344; P:cholesterol efflux; IDA:BHF-UCL.
DR   GO; GO:0042632; P:cholesterol homeostasis; IDA:BHF-UCL.
DR   GO; GO:0008203; P:cholesterol metabolic process; IDA:BHF-UCL.
DR   GO; GO:0034382; P:chylomicron remnant clearance; IMP:BHF-UCL.
DR   GO; GO:0007010; P:cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:0055089; P:fatty acid homeostasis; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0034380; P:high-density lipoprotein particle assembly; IDA:BHF-UCL.
DR   GO; GO:0034384; P:high-density lipoprotein particle clearance; IDA:BHF-UCL.
DR   GO; GO:0034375; P:high-density lipoprotein particle remodeling; IGI:BHF-UCL.
DR   GO; GO:0046907; P:intracellular transport; TAS:UniProtKB.
DR   GO; GO:0010877; P:lipid transport involved in lipid storage; ISS:BHF-UCL.
DR   GO; GO:0042158; P:lipoprotein biosynthetic process; IEA:Ensembl.
DR   GO; GO:0042159; P:lipoprotein catabolic process; IBA:GO_Central.
DR   GO; GO:0042157; P:lipoprotein metabolic process; TAS:Reactome.
DR   GO; GO:0015909; P:long-chain fatty acid transport; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0034374; P:low-density lipoprotein particle remodeling; IEA:Ensembl.
DR   GO; GO:0051651; P:maintenance of location in cell; IEA:Ensembl.
DR   GO; GO:1902430; P:negative regulation of beta-amyloid formation; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0030195; P:negative regulation of blood coagulation; IDA:BHF-UCL.
DR   GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IDA:ARUK-UCL.
DR   GO; GO:0032269; P:negative regulation of cellular protein metabolic process; IGI:ARUK-UCL.
DR   GO; GO:0045541; P:negative regulation of cholesterol biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0090370; P:negative regulation of cholesterol efflux; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0061000; P:negative regulation of dendritic spine development; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1902951; P:negative regulation of dendritic spine maintenance; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:0051055; P:negative regulation of lipid biosynthetic process; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1903001; P:negative regulation of lipid transport across blood brain barrier; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1900272; P:negative regulation of long-term synaptic potentiation; IDA:ARUK-UCL.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IDA:BHF-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IBA:GO_Central.
DR   GO; GO:1901215; P:negative regulation of neuron death; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; IDA:ARUK-UCL.
DR   GO; GO:1902999; P:negative regulation of phospholipid efflux; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0010544; P:negative regulation of platelet activation; IDA:BHF-UCL.
DR   GO; GO:1901627; P:negative regulation of postsynaptic membrane organization; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1901630; P:negative regulation of presynaptic membrane organization; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0090209; P:negative regulation of triglyceride metabolic process; IEA:Ensembl.
DR   GO; GO:0031102; P:neuron projection regeneration; IBA:GO_Central.
DR   GO; GO:0007263; P:nitric oxide mediated signal transduction; IDA:BHF-UCL.
DR   GO; GO:0097114; P:NMDA glutamate receptor clustering; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0033700; P:phospholipid efflux; IDA:BHF-UCL.
DR   GO; GO:0044794; P:positive regulation by host of viral process; IMP:AgBase.
DR   GO; GO:1902004; P:positive regulation of beta-amyloid formation; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0030828; P:positive regulation of cGMP biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0010875; P:positive regulation of cholesterol efflux; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0010873; P:positive regulation of cholesterol esterification; IDA:BHF-UCL.
DR   GO; GO:0060999; P:positive regulation of dendritic spine development; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1902952; P:positive regulation of dendritic spine maintenance; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0045807; P:positive regulation of endocytosis; IDA:ARUK-UCL.
DR   GO; GO:1905855; P:positive regulation of heparan sulfate binding; IDA:ARUK-UCL.
DR   GO; GO:1905860; P:positive regulation of heparan sulfate proteoglycan binding; IDA:ARUK-UCL.
DR   GO; GO:0046889; P:positive regulation of lipid biosynthetic process; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1903002; P:positive regulation of lipid transport across blood brain barrier; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0032805; P:positive regulation of low-density lipoprotein particle receptor catabolic process; IDA:BHF-UCL.
DR   GO; GO:0051044; P:positive regulation of membrane protein ectodomain proteolysis; IDA:BHF-UCL.
DR   GO; GO:1902998; P:positive regulation of neurofibrillary tangle assembly; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1901216; P:positive regulation of neuron death; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IDA:ARUK-UCL.
DR   GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; IDA:BHF-UCL.
DR   GO; GO:1902995; P:positive regulation of phospholipid efflux; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1901628; P:positive regulation of postsynaptic membrane organization; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1901631; P:positive regulation of presynaptic membrane organization; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0017038; P:protein import; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; IDA:BHF-UCL.
DR   GO; GO:0030516; P:regulation of axon extension; TAS:UniProtKB.
DR   GO; GO:1900221; P:regulation of beta-amyloid clearance; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0032489; P:regulation of Cdc42 protein signal transduction; IDA:BHF-UCL.
DR   GO; GO:1905890; P:regulation of cellular response to very-low-density lipoprotein particle stimulus; IDA:ARUK-UCL.
DR   GO; GO:1901214; P:regulation of neuron death; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0048168; P:regulation of neuronal synaptic plasticity; TAS:UniProtKB.
DR   GO; GO:1902947; P:regulation of tau-protein kinase activity; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0002021; P:response to dietary excess; IEA:Ensembl.
DR   GO; GO:0000302; P:response to reactive oxygen species; NAS:UniProtKB.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0043691; P:reverse cholesterol transport; IDA:BHF-UCL.
DR   GO; GO:0007271; P:synaptic transmission, cholinergic; TAS:UniProtKB.
DR   GO; GO:0019433; P:triglyceride catabolic process; IBA:GO_Central.
DR   GO; GO:0070328; P:triglyceride homeostasis; ISS:BHF-UCL.
DR   GO; GO:0006641; P:triglyceride metabolic process; IDA:BHF-UCL.
DR   GO; GO:0042311; P:vasodilation; IEA:Ensembl.
DR   GO; GO:0034447; P:very-low-density lipoprotein particle clearance; IDA:BHF-UCL.
DR   GO; GO:0034372; P:very-low-density lipoprotein particle remodeling; IDA:BHF-UCL.
DR   GO; GO:0019068; P:virion assembly; IMP:AgBase.
DR   InterPro; IPR000074; ApoA_E.
DR   Pfam; PF01442; Apolipoprotein; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alzheimer disease; Amyloidosis; Cholesterol metabolism;
KW   Chylomicron; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Glycation; Glycoprotein; HDL; Heparin-binding;
KW   Hyperlipidemia; Lipid metabolism; Lipid transport; Neurodegeneration;
KW   Oxidation; Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Secreted; Signal; Steroid metabolism; Sterol metabolism; Transport;
KW   VLDL.
FT   SIGNAL        1     18       {ECO:0000269|PubMed:7068630}.
FT   CHAIN        19    317       Apolipoprotein E.
FT                                /FTId=PRO_0000001987.
FT   REPEAT       80    101       1.
FT   REPEAT      102    123       2.
FT   REPEAT      124    145       3.
FT   REPEAT      146    167       4.
FT   REPEAT      168    189       5.
FT   REPEAT      190    211       6.
FT   REPEAT      212    233       7.
FT   REPEAT      234    255       8.
FT   REGION       80    255       8 X 22 AA approximate tandem repeats.
FT   REGION      158    168       LDL receptor binding.
FT                                {ECO:0000269|PubMed:2063194}.
FT   REGION      162    165       Heparin-binding.
FT                                {ECO:0000269|PubMed:3947350}.
FT   REGION      229    236       Heparin-binding.
FT                                {ECO:0000269|PubMed:3947350}.
FT   MOD_RES     143    143       Methionine sulfoxide.
FT                                {ECO:0000250|UniProtKB:P08226}.
FT   MOD_RES     147    147       Phosphoserine; by FAM20C.
FT                                {ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:26091039}.
FT   CARBOHYD     26     26       O-linked (GalNAc...) threonine.
FT                                {ECO:0000269|PubMed:23234360}.
FT   CARBOHYD     36     36       O-linked (GalNAc...) threonine.
FT                                {ECO:0000269|PubMed:23234360}.
FT   CARBOHYD     93     93       N-linked (Glc) (glycation) lysine.
FT   CARBOHYD    212    212       O-linked (GalNAc...) threonine.
FT                                {ECO:0000269|PubMed:19838169}.
FT   CARBOHYD    307    307       O-linked (GalNAc...) threonine.
FT                                {ECO:0000269|PubMed:19838169}.
FT   CARBOHYD    308    308       O-linked (GalNAc...) serine.
FT                                {ECO:0000269|PubMed:19838169}.
FT   CARBOHYD    314    314       O-linked (GalNAc...) serine.
FT                                {ECO:0000269|PubMed:23234360}.
FT   VARIANT      21     21       E -> K (in form E5; associated with
FT                                hyperlipoproteinemia and atherosclerosis;
FT                                dbSNP:rs121918392).
FT                                {ECO:0000269|PubMed:2760009}.
FT                                /FTId=VAR_000645.
FT   VARIANT      31     31       E -> K (in HLPP3; form E4 Philadelphia
FT                                and form E5-type; only form E4
FT                                Philadelphia is disease-linked;
FT                                dbSNP:rs201672011).
FT                                {ECO:0000269|PubMed:1674745}.
FT                                /FTId=VAR_000646.
FT   VARIANT      43     43       R -> C (in LPG; form E2 Kyoto;
FT                                dbSNP:rs121918399).
FT                                {ECO:0000269|PubMed:10432380,
FT                                ECO:0000269|PubMed:18077821}.
FT                                /FTId=VAR_042734.
FT   VARIANT      46     46       L -> P (in FH; unknown pathological
FT                                significance; form E4 Freiburg;
FT                                dbSNP:rs769452).
FT                                {ECO:0000269|PubMed:11042151,
FT                                ECO:0000269|PubMed:26802169}.
FT                                /FTId=VAR_000647.
FT   VARIANT      60     60       T -> A (in form E3 Freiburg;
FT                                dbSNP:rs28931576).
FT                                /FTId=VAR_000648.
FT   VARIANT      64     64       Q -> H (polymorphism; confirmed at
FT                                protein level; dbSNP:rs370594287).
FT                                {ECO:0000269|PubMed:22028381,
FT                                ECO:0000269|Ref.10}.
FT                                /FTId=VAR_014114.
FT   VARIANT      99     99       Q -> K (in form E5 Frankfurt).
FT                                /FTId=VAR_000649.
FT   VARIANT     102    102       P -> R (in form E5-type; no
FT                                hyperlipidemia; dbSNP:rs28931578).
FT                                /FTId=VAR_000650.
FT   VARIANT     117    117       A -> T (in form E3*; dbSNP:rs28931577).
FT                                /FTId=VAR_000651.
FT   VARIANT     124    124       A -> V (in form E3 Basel).
FT                                {ECO:0000269|PubMed:12864777}.
FT                                /FTId=VAR_016789.
FT   VARIANT     130    130       C -> R (in HLPP3; form E3**, form E4,
FT                                form E4/3 and some forms E5-type; only
FT                                form E3** is disease-linked;
FT                                dbSNP:rs429358).
FT                                {ECO:0000269|PubMed:11042151,
FT                                ECO:0000269|PubMed:12966036,
FT                                ECO:0000269|PubMed:8287539,
FT                                ECO:0000269|PubMed:9360638}.
FT                                /FTId=VAR_000652.
FT   VARIANT     145    145       G -> D (in FH; unknown pathological
FT                                significance; form E1 Weisgraber;
FT                                dbSNP:rs267606664).
FT                                {ECO:0000269|PubMed:26802169,
FT                                ECO:0000269|PubMed:8287539}.
FT                                /FTId=VAR_000653.
FT   VARIANT     145    145       G -> GEVQAMLG (in HLPP3; form E3 Leiden).
FT                                {ECO:0000269|PubMed:2556398}.
FT                                /FTId=VAR_000654.
FT   VARIANT     152    152       R -> Q (in form E2-type; no
FT                                hyperlipidemia; dbSNP:rs28931578).
FT                                /FTId=VAR_000655.
FT   VARIANT     154    154       R -> C (in HLPP3; form E2-type;
FT                                dbSNP:rs121918393).
FT                                /FTId=VAR_000657.
FT   VARIANT     154    154       R -> S (in HLPP3; form E2 Christchurch;
FT                                dbSNP:rs121918393).
FT                                {ECO:0000269|PubMed:22481068,
FT                                ECO:0000269|PubMed:8287539}.
FT                                /FTId=VAR_000656.
FT   VARIANT     160    160       R -> C (in HLPP3; form E3**;
FT                                dbSNP:rs387906567).
FT                                {ECO:0000269|PubMed:8287539}.
FT                                /FTId=VAR_000658.
FT   VARIANT     163    163       R -> C (in HLPP3 and FH; form E4
FT                                Philadelphia and form E2-type;
FT                                dbSNP:rs769455).
FT                                {ECO:0000269|PubMed:11042151,
FT                                ECO:0000269|PubMed:1674745,
FT                                ECO:0000269|PubMed:26802169}.
FT                                /FTId=VAR_000659.
FT   VARIANT     163    163       R -> H (in E3 Kochi; dbSNP:rs121918397).
FT                                /FTId=VAR_000660.
FT   VARIANT     163    163       R -> P (in LPG; form E2 Sendai;
FT                                dbSNP:rs121918397).
FT                                {ECO:0000269|PubMed:9176854}.
FT                                /FTId=VAR_042735.
FT   VARIANT     164    164       K -> E (in HLPP3; form E1 Harrisburg;
FT                                dbSNP:rs121918394).
FT                                /FTId=VAR_000662.
FT   VARIANT     164    164       K -> Q (in HLPP3; form E2**;
FT                                dbSNP:rs121918394).
FT                                /FTId=VAR_000661.
FT   VARIANT     167    167       Missing (in SBHD and FH; also found in
FT                                patients with a diagnosis of familial
FT                                combined hyperlipidemia).
FT                                {ECO:0000269|PubMed:11095479,
FT                                ECO:0000269|PubMed:16094309,
FT                                ECO:0000269|PubMed:22481068,
FT                                ECO:0000269|PubMed:22949395,
FT                                ECO:0000269|PubMed:24267230,
FT                                ECO:0000269|PubMed:26802169}.
FT                                /FTId=VAR_035015.
FT   VARIANT     170    170       A -> P (in form E3*; dbSNP:rs267606662).
FT                                /FTId=VAR_000663.
FT   VARIANT     176    176       R -> C (in HLPP3; forms E1 Weisgraber,
FT                                form E2 and form E3**; dbSNP:rs7412).
FT                                {ECO:0000269|PubMed:11042151,
FT                                ECO:0000269|PubMed:12966036,
FT                                ECO:0000269|PubMed:8287539}.
FT                                /FTId=VAR_000664.
FT   VARIANT     242    242       R -> Q (in form E2 Fukuoka;
FT                                dbSNP:rs267606663).
FT                                /FTId=VAR_000665.
FT   VARIANT     246    246       R -> C (in form E2 Dunedin;
FT                                dbSNP:rs121918395).
FT                                /FTId=VAR_000666.
FT   VARIANT     254    254       V -> E (in form E2 WG;
FT                                dbSNP:rs199768005).
FT                                {ECO:0000269|PubMed:8488843}.
FT                                /FTId=VAR_000667.
FT   VARIANT     262    263       EE -> KK (in HLPP3; form E7 Suita).
FT                                /FTId=VAR_000668.
FT   VARIANT     269    269       R -> G (in form E3 HB and form E4/3;
FT                                dbSNP:rs267606661).
FT                                {ECO:0000269|PubMed:8488843,
FT                                ECO:0000269|PubMed:9360638}.
FT                                /FTId=VAR_000669.
FT   VARIANT     270    270       L -> E (in form E1 HE; requires 2
FT                                nucleotide substitutions).
FT                                {ECO:0000269|PubMed:8488843}.
FT                                /FTId=VAR_000670.
FT   VARIANT     292    292       R -> H (in form E4 PD;
FT                                dbSNP:rs121918398).
FT                                {ECO:0000269|PubMed:8488843}.
FT                                /FTId=VAR_000671.
FT   VARIANT     314    314       S -> R (in form E4 HG; dbSNP:rs28931579).
FT                                {ECO:0000269|PubMed:8488843}.
FT                                /FTId=VAR_000672.
FT   STRAND       22     24       {ECO:0000244|PDB:2KC3}.
FT   HELIX        31     39       {ECO:0000244|PDB:2KC3}.
FT   TURN         40     42       {ECO:0000244|PDB:2KC3}.
FT   HELIX        43     60       {ECO:0000244|PDB:1GS9}.
FT   HELIX        63     70       {ECO:0000244|PDB:1GS9}.
FT   HELIX        73     96       {ECO:0000244|PDB:1GS9}.
FT   TURN         97     99       {ECO:0000244|PDB:1LE4}.
FT   HELIX       106    141       {ECO:0000244|PDB:1GS9}.
FT   TURN        143    145       {ECO:0000244|PDB:1NFN}.
FT   HELIX       149    179       {ECO:0000244|PDB:1GS9}.
FT   TURN        180    182       {ECO:0000244|PDB:1BZ4}.
FT   TURN        187    190       {ECO:0000244|PDB:2KC3}.
FT   HELIX       193    198       {ECO:0000244|PDB:2KC3}.
FT   STRAND      200    202       {ECO:0000244|PDB:2L7B}.
FT   HELIX       209    217       {ECO:0000244|PDB:2L7B}.
FT   HELIX       228    241       {ECO:0000244|PDB:2L7B}.
FT   HELIX       257    283       {ECO:0000244|PDB:2L7B}.
FT   HELIX       286    303       {ECO:0000244|PDB:1OEF}.
FT   STRAND      307    309       {ECO:0000244|PDB:2L7B}.
SQ   SEQUENCE   317 AA;  36154 MW;  91AFC04210A30689 CRC64;
     MKVLWAALLV TFLAGCQAKV EQAVETEPEP ELRQQTEWQS GQRWELALGR FWDYLRWVQT
     LSEQVQEELL SSQVTQELRA LMDETMKELK AYKSELEEQL TPVAEETRAR LSKELQAAQA
     RLGADMEDVC GRLVQYRGEV QAMLGQSTEE LRVRLASHLR KLRKRLLRDA DDLQKRLAVY
     QAGAREGAER GLSAIRERLG PLVEQGRVRA ATVGSLAGQP LQERAQAWGE RLRARMEEMG
     SRTRDRLDEV KEQVAEVRAK LEEQAQQIRL QAEAFQARLK SWFEPLVEDM QRQWAGLVEK
     VQAAVGTSAA PVPSDNH
//
